Filing No. Date ---------- ---------------- ------------------------------------ ------------ ---------- ----------- 155 X. Xxx Recombinant Methods and U.S. 561,024 12/13/83 Materials Applied to Micro- bial Expression of Erythro- poietin 155-CIP-1 X. Xxx Recombinant Methods and U.S. 582,185 2/21/84 Materials Applied to Micro- bial Expression of Erythro- poietin 155-CIP-2 X. Xxx Recombinant Methods and U.S. 655,841 9/28/84 Materials Applied to Micro- bial Expression of Erythro- poietin 155-CIP-3 X. Xxx Production of Erythropoietin U.S. 675,298 11/30/84 132 X. Xxxxx ATCC HB8209 - Its Monoclonal U.S. 463,724 2/4/83 Antibody to Xxxxxxxxxxxxxx XXXX XX0000/Xxxxxxxx
Filing No. Date -------- -------------- ------------------------------- ------------ ---------- --------- 106-C G. Bitter Expression of Exogenous U.S. 748,712 6/26/85 Polypeptides and Poly- (A continuation peptide Products Including of S.N. 412,707 Hepatitis B Surface Antigen filed 8/30/82 204 X. Xxxxxxxx Fermentation Methods for U.S. * 8/15/85 Hepatitis Vaccine Produc- tion 201 X. Xxxxxx Lysis Method and Buffer for U.S. * 8/15/85 Extraction of HBsAg from Yeast Cells *Information not yet available Exhibit D-3 ----------- INTERLEUKIN II --------------
Filing No. Date ------------------------------------------------------------------------------------------------------------------------ 138 X. Xxxxx Microbial Expression of U.S. 521,967 8/10/83 X. Xxxxxxxxx Interleukin II 138-CIP-1 X. Xxxxx Microbial Expression of U.S. 635,941 8/3/84 X. Xxxxxxxxx Interleukin II Canada 460,745 8/10/84 Israel 72643 8/10/84 Japan Via PCT US84/ 01252 8/9/84 EPO designating 84.109537.5 8/10/84 Austria Belgium France Germany Italy Luxembourg Netherlands Sweden Switzerland Liechtenstein United Kingdom -CIP-2 X. Xxxxx Microbial Expression of U.S. 717,334 3/29/85 X. Xxxxxxxxx Interleukin II Exhibit 10.5 9-30-85 ------- TECHNOLOGY LICENSE AGREEMENT ---------------------------- THIS TECHNOLOGY LICENSE AGREEMENT entered into this 30th day of September, 1985, by and between AMGEN, a California corporation having offices at 0000 Xxx Xxxxxxx Xxxx, Xxxxxxxx Xxxx, Xxxxxxxxxx 00000-0000 (said corporation hereinafter referred to as "AMGEN") and ORTHO PHARMACEUTICAL CORPORATION, a New Jersey corporation having offices at U.S. Xxxxx 000, Xxxxxxx, Xxx Xxxxxx 00000, (said corporation hereinafter referred to as "ORTHO").
Filing No. Filing Date UCC-3 Filing No. Filing Date Document CA SOS 9728360532 10/9/1997 CA SOS 9728360448 10/9/1997 CA SOS 9728360388 10/9/1997 CA SOS 97283C0448 10/9/1997 NY County Recorder 97PN49796 10/23/1997
Filing No. 01940537 filed on March 28, 2000 with the Wisconsin Secretary of State, naming Xxxxx Enterprises, Inc., Debtor and Norwest Bank, N.A., Secured Party (payment of the underlying Indebtedness anticipated on or about June 28, 2002);
Filing No. E40152 filed on May 22, 1973 with the Ohio Secretary of State, naming American Merchandising Associates, Inc. (n/k/a Spring Lake Merchandise, Inc.), Debtor and General Electric Company, Secured Party;
Filing No. Date --------- -------------- ------------------------------ ----------- ----------- -------------- 138 X. Xxxxx Microbial Expression of U.S. 521,967 8/10/83 X. Xxxxxxxxx Interleukin II 138-CIP-1 X. Xxxxx Microbial Expression of U.S. 635,941 8/3/84 X. Xxxxxxxxx Interleukin II Canada 460,745 8/10/84 Israel 72643 8/10/84 Japan Via PCT US84/ 01252 8/9/84 EPO designating 84.109537.5 8/10/84 Austria Belgium France Germany Italy Luxembourg Netherlands Sweden Switzerland Liechtenstein United Kingdom -CIP-2 X. Xxxxx Microbial Expression of U.S. 717,334 3/29/85 X. Xxxxxxxxx Interleukin II
Filing No. Date ----------- ----------- ---------------------------- ------- --------- ----------- 155 X. Xxx Recombinant Methods and U.S. 561,024 12/13/83 Materials Applied to Micro- bial Expression of Erythro- poietin 155-CIP-1 X. Xxx Recombinant Methods and U.S. 582,185 2/21/84 Materials Applied to Micro- bial Expression of Erythro- poietin 155-CIP-2 X. Xxx Recombinant Methods and U.S. 655,841 9/28/84 Materials Applied to Micro- bial Expression of Erythro- poietin 155-CIP-3 X. Xxx Production of Erythropoietin U.S. 675,298 11/30/84 Australia Xxx XXX XX00/ 00000 12/11/84 China 85106196 6/19/85 Canada 469,938 12/12/84 Czechoslovakia PV 4438-85 6/18/85 EPO designating 84308654.7 12/12/84 Austria Belgium France Germany Italy Luxembourg Netherlands Sweden Switzerland Xxxxxxxxxxxx United Kingdom * Information not yet available. Exhibit B --------- ERYTHROPOIETIN (Page 2) ---------------
Filing No. Date --------- ----------- ------- ---------- -------------- -------- Finland 852,377 6/14/85 Denmark Xxx XXX XX00/ 0000 00/00/00 X. Xxxxxxx G/277534-2 6/19/85 Greece * * Hungary 2404/85 6/18/85 Israel 73785 12/11/84 Japan Xxx XXX XX00/ 00000 12/11/84 Korea 7923/1984 12/13/84 New Zealand 201,501 12/10/84 Portugal * * South Africa 84/9625 12/11/84 Spain 538,519 12/12/84 USSR 3917560/04 6/19/85 * Information not yet available. Exhibit B --------- ERYTHROPOIETIN (Page 3) ---------------
Filing No. (Subdivision Name) Executed this Day of . (Day) (Month/Year) a corporation (Developer No. 1) (Name of State) By: (Signature) (Printed Name) (Title) a corporation qualified to do business in Colorado. (Developer No. 2) (Name of State) By: (Signature) (Printed Name) (Title)
